Horvath et al. have indicated that the poor efficacy of tumor immunotherapy is related to the infiltration of Tregs and MDSCs [18], whereas IDO is a critical promoter of Treg and MDSC proliferation/activation [19]. The gene discussed is IDO1; the disease is neoplasm.